The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women
about
Green fluorescent protein fused to peptide agonists of two dissimilar G protein-coupled receptors: novel ligands of the bradykinin B2 (rhodopsin family) receptor and parathyroid hormone PTH1 (secretin family) receptor.Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA.Biochemical markers for assessment of calcium economy and bone metabolism: application in clinical trials from pharmaceutical agents to nutritional products.Breast cancer and osteoporosis - management of cancer treatment-induced bone loss in postmenopausal women with breast cancer.Trends in the incidence of hip fracture in Gran Canaria, Canary Islands, Spain: 2007-2011 versus 1989-1993Cancer Treatment-Induced Bone Loss in women with breast cancerInteraction between bone and muscle in older persons with mobility limitationsRecommendations for preventing fracture in long-term care.Medication burden of Saudi Arabian women receiving antiresorptive therapyIn Vivo Study on the Pharmacological Interactions between a Chinese Herbal Formula ELP and Antiresorptive Drugs to Counteract OsteoporosisClinical impact of recent genetic discoveries in osteoporosis.Alendronate versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled Trials.Hip and other fragility fracture incidence in real-world teriparatide-treated patients in the United States.Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis.Management of osteoporosis of the oldest old.FRAX for fracture prediction shorter and longer than 10 years: the Manitoba BMD registry.Genetic and acquired factors influencing the effectiveness and toxicity of drug therapy in osteoporosis.Real-world evidence of raloxifene versus alendronate in preventing non-vertebral fractures in Japanese women with osteoporosis: retrospective analysis of a hospital claims database.Age-period-cohort effects in the incidence of hip fractures: political and economic events are coincident with changes in risk.Fractures and mortality in relation to different osteoporosis treatments.Trends in osteoporotic hip fracture epidemiology over a 17-year period in a Spanish population: Alcorcón 1999-2015.Effectiveness of Oral Bisphosphonates in Reducing Fracture Risk Among Oral Glucocorticoid Users: Three Matched Cohort Analyses.Economic Analysis of Bisphosphonate Use after Distal Radius Fracture for Prevention of Hip Fracture.Real-world effectiveness of osteoporosis therapies for fracture reduction in post-menopausal women.Recommandations en vue de la prévention des fractures dans les établissements de soins de longue durée.Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancerEfficacy and Safety of the Biosimilar Recombinant Human Parathyroid Hormone Cinnopar in Postmenopausal Osteoporotic Women: A Randomized Double-blind Clinical TrialChange in Trabecular Bone Score (TBS) With Antiresorptive Therapy Does Not Predict Fracture in Women: The Manitoba BMD Cohort
P2860
Q34286441-B57CD8C0-FF06-430B-A70A-EBCBEBF4BE8CQ34459547-B7511974-8DBF-4076-9A1F-54F5B52E2F0AQ35017714-6F5EEC37-D56D-4F9B-8DAE-11A614A4BD84Q35066907-C6BFACCE-4199-4F7F-BF6D-DA3042359BD4Q35601608-D88D5981-11A2-417F-89B3-6FE156790928Q35632616-B232C73D-8B2D-48DB-8712-7EF72AA8493FQ36100758-88803878-8774-4F55-AF2D-8434F5E0A771Q36176941-A5C11694-2EE0-43C7-9128-E879609B17EDQ36311638-BC14A855-0819-4A35-BCB8-D30CB6736CAAQ36369348-4749C1D3-5F06-4F95-A07E-FCBDE83E8DD9Q37230278-E4D1035E-1249-49FE-9846-0B71E01DCE72Q37551824-78CB3785-13D6-4582-9FC7-75E7A13B96A8Q37639393-D53022E5-D6D8-4D19-B14A-0ECEE8069AC0Q38167249-82D611E8-C272-4639-B5D4-1511E8BD249AQ38229503-6E1A79EE-DDF2-4E29-A92B-C18E4300C779Q38737117-AEEE3A6E-518B-44D4-840F-75074EE9953DQ38739527-59865D0F-63EB-4C0F-9922-4387E2DD05AFQ39061355-D8443C3E-3CC5-496E-A813-57865C9ED2F7Q39360356-438C902A-7FB6-4C3E-BE4E-C6EECD92C757Q43577539-95B2DD1F-0B24-469E-8BD2-0A40204BB6ADQ47626392-94F6B472-256C-40CD-B3C6-09F77BB88871Q47722324-50ECFEC1-AD8D-43F2-B0C0-B61413CD233FQ49332607-89BAD15A-7214-47D9-BD20-32F97F57AB10Q51736759-C8917242-B023-4EEF-A34A-7BAC89ED29EBQ54856088-ECF5241F-25D5-4181-8F9D-182287BE08EAQ57218488-0D2BFA29-36FF-4D69-98B0-907DC050DA44Q57494538-C3DF3A8F-2FFA-4578-B9AB-817656F95DF8Q57710906-22FF785C-1AF8-43FC-B557-BE615D374937
P2860
The relative efficacy of nine osteoporosis medications for reducing the rate of fractures in post-menopausal women
description
2011 nî lūn-bûn
@nan
2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The relative efficacy of nine ...... tures in post-menopausal women
@ast
The relative efficacy of nine ...... tures in post-menopausal women
@en
The relative efficacy of nine ...... tures in post-menopausal women
@nl
type
label
The relative efficacy of nine ...... tures in post-menopausal women
@ast
The relative efficacy of nine ...... tures in post-menopausal women
@en
The relative efficacy of nine ...... tures in post-menopausal women
@nl
prefLabel
The relative efficacy of nine ...... tures in post-menopausal women
@ast
The relative efficacy of nine ...... tures in post-menopausal women
@en
The relative efficacy of nine ...... tures in post-menopausal women
@nl
P2093
P2860
P356
P1476
The relative efficacy of nine ...... tures in post-menopausal women
@en
P2093
Alexandra Papaioannou
Eleanor Pullenayegum
Jonathan D Adachi
Robert B Hopkins
Ron Goeree
P2860
P2888
P356
10.1186/1471-2474-12-209
P5008
P577
2011-09-26T00:00:00Z
P5875
P6179
1026992168